First author
|
Year
|
Age
|
Sex
|
Stage
|
Preoperative therapy
|
Clinical response
|
Pathological response
|
Prognosis
|
---|
Zuiki [23]
|
2009
|
50
|
Male
|
II
|
CRT (FP+62 Gy)
|
PR
|
ND
|
36 months alive
|
Zuiki [23]
|
2009
|
66
|
Male
|
I
|
CRT (FP+40.2 Gy)
|
PR
|
ND
|
19 months alive
|
Kobayashi [24]
|
2010
|
68
|
Male
|
III
|
CRT (S-1/CDDP+40 Gy)
|
PR
|
npCR
|
60 months alive
|
Kobayashi [24]
|
2010
|
64
|
Male
|
III
|
CRT (FP+38 Gy)
|
SD
|
npCR
|
11 months dead
|
Kuo [7]
|
2010
|
68
|
Male
|
III
|
CRT (ND)
|
ND
|
ND
|
27 months alive
|
Kuo [7]
|
2010
|
45
|
Male
|
IV
|
CRT (ND)
|
ND
|
ND
|
6 months alive
|
Kobayashi [25]
|
2015
|
69
|
Male
|
II
|
FP
|
SD
|
NC
|
60 months alive
|
Present case
|
2016
|
73
|
Male
|
III
|
DCF
|
SD
|
npCR
|
12 months alive
|
- CRT chemoradiotherapy, PR partial response, npCR near pathological complete response, SD stable disease, FP 5-fluorouracil and cisplatin, S-1/CDDP S-1 and cisplatin, NC no change, DCF docetaxel, cisplatin, and 5-fluorouracil, ND not described